Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024

SAN FRANCISCO and SINGAPORE, May 13, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced two presentations at the 20th Annual PEGS Boston summit being held from May 13-17, 2024. Data from the first presentation demonstrates the ability to direct antibodies and antibody-drug conjugates (ADCs) to rationally selected epitopes of interest on challenging disease-associated proteins. Data from the second presentation show how a novel dual-payload ADC approach has the potential to address resistance and improve the therapeutic window of ADCs.

“The data presented at PEGS show for the first time how our proprietary fourth generation antibody-drug conjugate (ADC) platform leverages novel linker and dual-payload technologies to overcome the resistance observed with earlier generation single payload ADCs. Our ADC technology has the potential to treat a large number of patients that have either intrinsic or acquired resistance to currently approved ADCs,” said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. “We will also showcase how our proprietary Rational Antibody Discovery platform engineers immune responses in transgenic mice models so that resulting ADCs and antibodies bind to the key epitopes on disease-associated proteins for optimal drug properties. These data continue to support our belief that our next-generation ADC platform can generate best-in-class ADCs that address payload resistance, optimize tumor specificity, and enhance payload delivery, and therefore maximize the anti-tumor potential of ADCs.”

Presentation details:

Title: Engineering Immune Responses for Epitope-Focused Antibody Discovery
Presenter: Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer
Session: Display of Biologics - Novel Platforms
Date/Time: Monday, May 13, 2024, 1:45 p.m. ET

Title: Overcoming Payload Resistance with Dual-Payload ADCs
Presenter: Ben Ayers, DPhil, Vice President, Antibody-Drug Conjugates
Session: Driving Clinical Success in Antibody Drug Conjugates - Novel payloads and MOAs
Date/Time: Friday, May 17, 2024, 9:30 a.m. ET

About Hummingbird Bioscience’s ADC Platform

The 4th generation ADC platform developed by Hummingbird Bioscience aims to address the key limitations in efficacy and safety of current approved ADCs. The ADC platform combines the company’s AI-enabled Rational Antibody Discovery Platform and proprietary linker and dual-payload technologies to unlock the power of dual-payload approaches against the most important disease-associated proteins. The platform engineers potentially best-in-class ADCs that address payload resistance, optimize payload delivery and tumor specificity, and maximize anti-tumor cytotoxic potential.

About Hummingbird Bioscience’s Rational Antibody Discovery Platform

The Rational Antibody Discovery (RAD) platform is designed to address the challenges of traditional antibody approaches. This technology enables the company to identify critical functional regions of a target protein using mAbPredict, a machine learning-enabled technology platform that identifies optimal regions to target, and then drives production of antibodies against these epitopes using mAbHits, a proprietary immuno-engineering technology that directs the antibody response to pre-determined epitopes of interest in the proprietary transgenic HMBD Abvantage mouse. Unlike classical approaches to antibody discovery that have limited control over antibody binding regions, and hence, ability to target optimal epitopes, mAbHits ensures in vivo generation and affinity maturation of antibodies against only the optimal epitope. This systematic and rational approach to antibody discovery opens up the potential of discovering antibodies to specific regions of many important “hard targets” that have not been drugged or are inadequately drugged to date. The RAD platform has produced multiple antibodies and ADCs that effectively target disease-associated proteins, including two antibodies that are currently in Phase I trials (HMBD-001 and HMBD-002) and a recently out-licensed ADC (HMBD-501) that will enter the clinic in 2024.

About Hummingbird Bioscience

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. To address key challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is building a pipeline of next-generation ADCs using its proprietary antibody discovery and linker/payload platforms. The company has a pipeline of ADCs in preclinical development and other novel biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I and a recently out-licensed ADC (HMBD-501) that will enter the clinic this year. The Hummingbird Bioscience approach combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.

For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.

Contacts:

Media
Crystal Ho
c.ho@hummingbirdbio.com
media@hummingbirdbio.com
+65 6979 5580

Investors
investors@hummingbirdbio.com


Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024

THỦ THUẬT HAY

Hướng dẫn sửa lỗi Bluetooth bị mất trên cài đặt Settings Windows 10

Đôi khi trong một số trường hợp khi mở cửa sổ cài đặt Settings và bạn phát hiện ra rằng Bluetooth bị mất.

Cách tùy chỉnh giao diện mới của Firefox Quantum

Firefox Quantum có nhiều cải tiến bao gồm cả một giao diện người dùng Photon mới. Photon thay thế giao diện 'Australis' đã được sử dụng từ năm 2014 và có nhiều tùy chọn tùy chỉnh. Bài viết này sẽ giới thiệu cho các bạn

Cách viết ghi chú mũi tên trong Word

Trong Words, khi biểu diễn một đoạn văn bản cần sơ đồ, hình khối có lẽ biểu tượng mũi tên sẽ được người dùng sử dụng nhiều nhất. Đặc biệt viết chú thích lên mũi tên sẽ làm tăng thêm tính trực quan của biểu đồ mà bạn

Cách kích hoạt Game Mode trên iPhone để chơi game không bị làm phiền

Cách kích hoạt Game Mode trên iPhone, giúp game thủ thoải mái chơi game mà không sợ bị làm phiền​ bởi các thông báo khó chịu ảnh hưởng lúc giải trí.

9 ứng dụng dành cho Android đang miễn phí và giảm giá

Hiện tại, trên cửa hàng Google Play đang cho phép người dùng tải về miễn phí 9 ứng dụng và trò chơi bản quyền khá hay. Nếu đang sở hữu một chiếc Android phone thì mời bạn cùng xem và nhanh tay chọn lựa cho mình một vài

ĐÁNH GIÁ NHANH

Đánh giá sức mạnh của Snapdragon 8+ Gen 1 trên Xiaomi

Thời gian trước khi Snapdragon 8 Gen 1 ra mắt đã gây thất vọng trong hầu hết các bài thử nghiệm do điều chỉnh quá nặng, hiệu suất kém và nhiệt kém. Chính vì thế NSX Qualcomm đã có sự điều chỉnh nâng cấp và hoàn thiện

Đánh giá những điểm mới trên Galaxy S7

Galaxy S7 vừa được Samsung bán ra ở một số thị trường, đây có phải là một chiếc smartphone đáng để người dùng đầu tư trong năm nay?